Navigation Links
Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference

KING OF PRUSSIA, Pa., May 19, 2011 /PRNewswire/ -- Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011. CSL Behring is a global biotherapeutics company specializing in plasma-derived and recombinant therapies and is a subsidiary of CSL Limited (ASX:CSL).

CSL627, a unique single-chain recombinant factor VIII (rFVIII) studied for treatment of hemophilia A, will enter phase I clinical testing.

The structure of factor VIII (FVIII) is based on two linked protein chains—a heavy one and a light one. Under certain conditions, this structure can dissociate, resulting in the formation of separated, or "dissociated," FVIII chains. CSL627 uses a strong, covalent bond that connects the light and heavy chains, thereby creating a single-chain rFVIII.

In-house studies have shown that the molecular integrity of CSL627 is significantly increased using this single-chain design, resulting in a homogenous product that may be more stable than currently available options. In addition, in-vitro studies have shown that CSL627 demonstrates a very strong affinity for von Willebrand factor (VWF) and a faster and more efficient binding to VWF than is demonstrated in wild-type FVIII. The FVIII/VWF complex plays an important role in the physiological activity and clearance of FVIII and has been shown to have an influence on the presentation of FVIII to the immune system.

"For more than 90 years, CSL Behring has been committed to providing safe and effective therapies to help improve the lives of patients and caregivers affected by hemophilia A and other rare bleeding disorders," said  Dr. Andrew Cuthbertson, Chief Scientist, CSL Limited. "Developing innovative therapeutic solutions to serious medical conditions is one important way to do that. Therefore, CSL Behring seeks to further expand its broad portfolio of products for the hemophilia community, starting with research into a single-chain rFVIII and other promising therapies."

The research leading to the initiation of the studies that CSL Behring is now conducting is the result of collaboration across the CSL Behring research sites in Marburg, Germany, in King of Prussia, PA, USA, and at facilities operated by CSL Limited in Melbourne, Australia.

CSL Behring is also at work on two recombinant fusion proteins (FP) linking coagulation factors with albumin. Both are in testing to demonstrate an extension of factor half life. One, rVIIa-FP (CSL689), is a recombinant factor VIIa albumin fusion protein for the treatment of patients with hemophilia A or B who have developed inhibitory antibodies. The other, rIX-FP (CSL654), is a recombinant fusion protein linking coagulation factor IX with albumin. It is currently recruiting for phase I studies.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema, and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit

Media Contacts:
Sheila A. Burke
Director, Worldwide Commercial Public Relations and Communications
CSL Behring
1020 First Avenue
King of Prussia, PA 19406
484-919-2618 (mobile, US)

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Anaphore to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference
2. Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
3. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
4. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
5. New and Updated Online Tutorials for Ensembl Legacy and Overview of Genome Browsers
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.
7. Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
9. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on The Medical House PLC
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):